FDA Approves Alhemo for Patients with Hemophilia

Routine prophylaxis to prevent or reduce bleeding

For Patients with Hemophilia A or B with Inhibitors

The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with:

  • Hemophilia A with factor VIII inhibitors, or
  • Hemophilia B with factor IX inhibitors.

What It Is

  • Alhemo is a subcutaneous (under the skin) injection, taken daily.
  • It’s designed for patients who have developed inhibitors — antibodies that block standard clotting factor treatments.

Effectiveness

  • In a global phase 3 trial, Alhemo reduced annual bleeding rates by 86% compared to no prophylaxis.
  • Participants included 91 adults and 42 adolescents with hemophilia A or B, with inhibitors.

Safety Info

  • Most common side effects: Injection site reactions and hives.
  • May cause hypersensitivity (rash, itching, abdominal pain) and increased risk of blood clots.
  • Not recommended for patients with serious allergies to the drug or its ingredients.

Special FDA Designations

  • Priority Review
  • Orphan Drug status (for rare conditions)

Alhemo offers a new preventative option for a high-risk hemophilia population where standard clotting therapies may fail.

More novel drug approvals.

Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.

More approved novel drugs

FDA Alhemo Approval Notice

News

FDA Enforcement

Safety Alerts

Medical Devices

Pharma

New Drugs

Drug Shortages

Formaldehyde in Hair Smoothing Products: Know the Risks

Know the Risks Before You Straighten Thinking of straightening or smoothing your hair? Many salon hair treatments release formaldehyde gas — a known human carcinogen — when heated. This chemical can pose serious short- and long-term health risks to both clients and...

FDA: Do Not Use OTC Products to Remove Moles or Skin Tags

FDA: Do Not Use OTC Products to Remove Moles or Skin Tags Thinking about removing a mole, skin tag, or other skin lesion at home? The FDA strongly advises against it. There are no FDA-approved prescription or over-the-counter (OTC) products for removing moles,...

FDA Alert: Baxter Recalls Spectrum Infusion Pumps

Baxter Spectrum Infusion Pump Alert Date: July 2025Device: Sigma Spectrum Infusion System (V6 and V8 Platforms)Manufacturer: Baxter HealthcareIssue Type: Urgent Medical Device RecallFDA Status: High-risk; active monitoring in progress The FDA has issued an early alert...